STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2026

Mar 17, 2026

==> picture [123 x 39] intentionally omitted <==

March 17, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Symbol: STAR

Dear Madam/ Sirs,

Sub: Disclosure under Regulation 30 of SEBI Listing Regulations

This has reference to the press release issued by the Company today titled “Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz”.

In this regard, please find enclosed herewith disclosure under Regulation 30 of SEBI Listing Regulations.

This is for your information and records.

Thanks & Regards, For Strides Pharma Science Limited,

MANJULA Digitally signed by MANJULA RAMAMURTHY RAMAMURTHY Date: 2026.03.17 17:46:53 +05'30'

Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No. A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Tel: +91 80 6784 0000 Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199

==> picture [123 x 39] intentionally omitted <==

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular dated January 30, 2026

Details relating to acquisition of Multiple Generic Brands from Sandoz

==> picture [440 x 431] intentionally omitted <==

----- Start of picture text -----

Particulars Remarks
1 Name of the entities with Parties to the agreement are:
whom agreement is signed
Strides Pharma International AG, Switzerland (SPIAG) , a
step‑down subsidiary of the Company
Sandoz AG, Switzerland and its group entities
(collectively referred to as “ Sandoz ”)
Strides Pharma Global Pte. Limited, Singapore (SPG), a
step‑down wholly owned subsidiary of the Company, as
Corporate Guarantor on behalf of SPIAG.
2 Area of Agreement SPIAG has executed definitive agreements with Sandoz for
acquisition and in‑licensing of certain branded generic products
Domestic/ International across the Sub‑Saharan Africa (SSA) region.
3 Scope of Business The transaction covers four key markets—Western Sahara,
Operations of the Agreement Ghana, Nigeria, and Kenya—where Strides has an established
operating presence.
Rationale and benefit
expected The integration of Strides’ existing operations with the Sandoz
portfolio is expected to position Strides among the top five
pharmaceutical companies in the SSA region by sales, and
among the top two within its represented markets.
The portfolio comprises multiple established brands across the
anti‑infective, cardiovascular, and dermatology segments.
Several of these products individually record annual sales
exceeding USD One Million, significantly bolstering the
existing business meaningfully.
4 Share Exchange Ratio Not applicable
----- End of picture text -----

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Tel: +91 80 6784 0000 Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199

==> picture [123 x 39] intentionally omitted <==

#	Particulars	Remarks
5	Details of Consideration	The upfront consideration for the proposed transaction is USD 12 Million, payable at closing. The transaction also provides for royalty payments to Sandoz based on a percentage of net sales of Distribution Products. The transaction is subject to customary closing conditions, including antitrust filings in one or more jurisdictions, as may be required. As part of the transaction, Strides Pharma Global Pte. Limited, Singapore (SPG), a step‑down wholly owned subsidiary of the Company and Holding Company of SPIAG, shall provide a guarantee to Sandoz to secure the payment obligations of SPIAG, as under:  A guarantee securing the upfront payment of USD 12 million, which will remain valid until closing and will be released upon completion of payment by SPIAG.  A guarantee to secure the payment of yearly royalty on Distribution Products, the amount of which is variable and linked to sales performance during each year.
6	Significant Terms & Conditions of the Agreement	The portfolio being transacted includes brands that are being fully acquired by Strides, as well as certain brands that Strides is in‑licensing from Sandoz. The arrangement also provides for yearly royalty payments to the Sandoz based on a percentage of net sales for the Distribution Products. The said transaction is expected to achieve closure by end of Q2 FY 27 (Quarter Ending 30th September 2026).

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Tel: +91 80 6784 0000 Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199

==> picture [123 x 39] intentionally omitted <==

==> picture [440 x 205] intentionally omitted <==

----- Start of picture text -----

Particulars Remarks
7 Whether the acquisition The said transaction with Sandoz is not a Related Party
would fall within related Transaction.
party transactions and
whether the promoter/ Transaction between SPIAG and SPG are inter-company
promoter group/ group transactions and are considered as Related Party Transactions.
companies have any interest And these RPT are at arms’ length.
in the entity being acquired?
Promoter/ Promoter Group of Strides do not have any interest in
If yes, nature of interest and the said transactions.
details thereof and whether
the same is done at “arm’s
length.
8 Size of entities Not applicable for the said transaction with Sandoz.
----- End of picture text -----

---

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com

==> picture [123 x 39] intentionally omitted <==

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular dated January 30, 2026

Details related to Corporate Guarantee provided by Strides Pharma Global Pte. Limited, Singapore, a step-down wholly owned subsidiary of the Company

#	Particulars	Remarks
1	Name of party for which such guarantee/ indemnity/ surety was given.	Strides Pharma Global Pte. Limited, Singapore (SPG),a step‑down wholly owned subsidiary of the Company, has provided Corporate Guarantor to Sandoz AG, Switzerlandand its group entities (collectively referred to as “Sandoz”) on behalf of Strides Pharma International AG, Switzerland (SPIAG), a step‑down subsidiary of the Company
2	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at “arm’s length	The said transaction with Sandoz is not a Related Party Transaction. Transaction between SPIAG and SPG are inter-company transactions and are considered as Related Party Transactions. And these RPT are at arms’ length. Promoter/ Promoter Group of Strides do not have any interest in the said transactions.
3	Brief details of such guarantee viz.  Brief details of agreement entered, if any  Significant terms and conditions  Amount of guarantee	SPIAG has executed definitive agreements with Sandoz for the acquisition and in‑licensing of certain branded generic products across the Sub‑Saharan Africa (SSA) region. As part of the transaction, Strides Pharma Global Pte. Limited, Singapore (SPG), a step‑down wholly owned subsidiary of the Company and Holding Company of SPIAG, shall provide a guarantee to Sandoz to secure the payment obligations of SPIAG, as follows:  A guarantee securing the upfront payment of USD 12 million, which will remain valid until closing and will be released upon completion of payment.  A guarantee to secure the payment of yearly royalty on Distribution Products, the amount of which is variable and linked to sales performance during each year.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com

==> picture [123 x 39] intentionally omitted <==

==> picture [425 x 27] intentionally omitted <==

----- Start of picture text -----

Particulars Remarks
----- End of picture text -----

# Particulars Remarks	# Particulars Remarks	# Particulars Remarks
4	Impact of Corporate Guarantee on the Listed Entity/ Guarantor	The said guarantee shall be recognized as a contingent liability in the books of SPG. There is no material financial impact arising from the said guarantee in the books of Strides Pharma Science Limited, India, the listed entity.

---

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com